Clinical Trial Update: A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing tislelizumab versus chemotherapy as second-line treatment in advanced esophageal squamous cell carcinoma has completed and results are p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Chemotherapy (chemotherapy)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | Status: COMPLETED | Results posted: 2023-12-29